Coil Assisted Flow Diversion Safety and Performance Study

Intracranial Aneurysm Clinical Trial

— CAFI  

Official title:

Coil Assisted Flow Diversion: A Prospective, Single Arm, Multi-center Study to Assess the Safety and Performance of Neqstent in Adjunctive Therapy (CAFI Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04187573
• Other study ID #: DNQS428-01
• Status: Completed
• Phase: N/A
• Start date: January 21, 2020
• Est. completion date: November 1, 2023

Study information

• Verified date: April 2024
• Source: Cerus Endovascular, Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cerus Endovascular is sponsoring a prospective, single arm, multi-center study to document the safety and performance of Neqstent in adjunctive therapy. The purpose of the study is to document safety and performance of the Neqstent in adjunctive therapy in treatment for patients with intracranial aneurysms (IA).

Description:

Neqstent is designed as an adjunctive therapy for patients with unruptured and failed bifurcation aneurysm embolizations. Neqstent can be positioned at the neck of the aneurysm with or without existing coils and other embolization products. Embolization coils should be added to fill the dome of the aneurysm after placement of Neqstent.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: November 1, 2023
• Est. primary completion date: June 17, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Patient's indication for treatment of unruptured IAs according to the national/international guidelines.

2. Age 18-80 years at screening

3. Patients who are suitable for non-emergency endovascular embolization of saccular IAs

4. IA located at a bifurcation in the anterior or posterior circulation with dimensions consistent with implant size selection guidelines included in the IFU

5. Patient has the necessary mental capacity to participate and is willing and able to participate in the study for the duration of the study follow-up and is able to comply with study requirements

6. Patient able to able to give their informed consent can be included in this study. This must be demonstrated by means of a personally signed and dated informed consent document indicating that the subject has been informed of and understood all pertinent aspects of the study.

Exclusion Criteria:

1. Ruptured aneurysm

2. Patient anatomy or physiology considered unsuitable for endovascular treatment

3. Any patient anatomy, physiology, existing implants with failed aneurysm embolization that would interfere with the ability for Neqstent to seal at the neck of the aneurysm. (i.e., compacted coils in close proximity to the neck that prevent good apposition of the Neqstent to the wall of the aneurysm, stent and/or stent-like devices whose struts span the aneurysm neck to retain the coil mass that inhibit access and/or successful Neqstent seating at the aneurysm neck, and/or any aneurysm that has a failed device and confirmed thrombus-burden inside the aneurysm sac)

4. Contraindication for arterial access

5. Largest measured IA neck diameter >8 mm or <3 mm

6. Target IA contains other devices/implants (e.g., coils) that will prevent complete expansion of Neqstent

7. Known allergy to platinum, nickel or titanium

8. Known allergy to contrast agents

9. Contraindication to anticoagulants or platelet inhibitor medication

10. Stenosis of the target IA's parent vessel >50%

11. Anticoagulation medications such as warfarin that cannot be discontinued.

12. Pregnant, breastfeeding or women of childbearing potential not on adequate birth control (only women with a highly effective method of contraception [oral contraception or intra-uterine device] or sterile women can be enrolled to the study)

13. Acute / chronic renal failure (including dialysis); Creatinine > 2.00 mg/dl or > 182 µmol/L

14. Myocardial Infarction, Stroke or TIA within the last 6 months

15. Any other medical issue within the brain that precludes the device implantation such as brain surgery, radiation in the target area of intervention, acute traumatic craniocerebral injury, etc.

16. Other medical conditions that cause an inability to comply with study requirements and/or that could increase the risk of neurovascular procedures or death within 2 years (e.g., liver failure, cancer, heart failure, chronic obstructive pulmonary disease, immunosuppression, neural disease, and hematologic disorders etc.)

17. Participating in another study with investigational devices or drugs that would confound the effects of the study outcomes

18. The presence of condition that may create unacceptable risk during the aneurysm embolization procedure

Related Conditions & MeSH terms

• Aneurysm
• Intracranial Aneurysm

Intervention

Device:
• Neqstent
Adjunctive device providing stable aneurysm neck coverage for the placement of embolization coils within the aneurysm sac and long term stable occlusion of the aneurysm.

Locations

Country	Name	City	State
Austria	Christian Doppler Klinikum	Salzburg
Canada	Alberta Health Sciences	Edmonton	Alberta
Denmark	Odense University Hospital	Odense
Germany	UK Hamburg	Hamburg
Germany	UKSH Kiel	Kiel
Germany	Klinikum der Universität München	Munich
Switzerland	Inerespital Basel	Basel

Sponsors (1)

Lead Sponsor	Collaborator
Cerus Endovascular, Ltd

Countries where clinical trial is conducted

Austria,  Canada,  Denmark,  Germany,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of subjects with death of any non-accidental cause or any major disabling stroke after treatment or major disabling stroke or death due to neurological cause.		From day 31 to 6 months after treatment
Primary	The occlusion rate as adjudicated by a core laboratory.	Success will be defined as complete occlusion demonstrated by a Grade 1 using the Raymond Roy Scale.	6 months

External Links

•   Sponsor Web-site